RLAY Q3 2023 Earnings — Relay Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RLAYRelay Therapeutics, Inc.

$2B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$25M+7226.2% YoY

Gross Profit

-$56M-223.4% margin

Operating Income

-$74M-291.9% margin

Net Income

-$66M-260.8% margin

EPS (Diluted)

$-0.54

QoQ Revenue Growth

+21078.2%

Cash Flow

Operating Cash Flow

-$75M

Free Cash Flow

-$76M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$907M

Total Liabilities

$129M

Stockholders' Equity

$778M

Cash & Equivalents

$151M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$25M	$344,000	+7226.2%
Gross Profit	-$56M	-$67M	+15.4%
Operating Income	-$74M	-$86M	+14.3%
Net Income	-$66M	-$84M	+21.9%